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Context. The plant Citrus maxima Merr. (Rutaceae), commonly known as shaddock or pomelo is indigenous to tropical parts of
Asia. The objective of present study is to evaluate the methanol extract of Citrus maxima leaves for its antitumor activity against
Ehrlich’s Ascites Carcinoma cell in Swiss albino mice. Experimental design. The antitumor activity of methanol extract of Citrus
maxima leaves (MECM) was evaluated against Ehrlich Ascites Carcinoma (EAC) cell line in Swiss albino mice. 2 × 106 cells were
inoculated in diﬀerent groups of animals. MECM (200 and 400mg/kg BW i.p.) was administered for nine consecutive days. On
day 10th half the animals of diﬀerent groups were sacriﬁced for determination of tumor and haematological parameters and the
rest half were kept with suﬃcient food and water ad libitum for determination of increase in life span. Result and Discussions.O r a l
administration of the extract at the doses of 200 and 400mg/kg signiﬁcantly decreased tumor parameters such as tumor volume,
viable tumor cell count and increased body weight, hematological parameters and life span in respect of the EAC control mice.
Conclusion. Experimental design exhibits signiﬁcant antitumor activity of the extract (MECM) in a dose dependant manner.
1.Introduction
Cancer, otherwise termed as Malignant Neoplasm, is a class
ofdiseasesinwhichagroupofcellsshowabnormalprolifera-
tion of cells, invasion and sometimes metastasis. These three
are the characters that diﬀerentiate malignant neoplasms
from benign tumors that they do not divide abnormally
beyond normal limits, do not invade or metastasize [1]. The
aim of current research has been the identiﬁcation of natural
and synthetic compounds that can be used in the prevention
and/or treatment of cancer. Plants have been regarded as a
potential source of cancer chemoprevention drug discovery
and development [2].
Citrus maxima and C. grandis (family: Rutaceae) are
both currently used for the shaddock or pomelo. Although
C. grandis (L.) Osbeck is more frequently used C. maxima
(J. Burman) Merrill is correct under the International Code
of Botanical Nomenclature [3].
The pulp is stated to possess the following properties
as reported in ancient and medieval literature: appetizer,
antitoxic, cardiac stimulant, and stomach tonic [4].
The major ﬂavanones of pomelo are neohesperidin
and naringin, which are high in the seed in case of unripe
citrus fruits [5] and its extract showed antioxidant activity
through free radical-scavenging in vitro and to reduce
reactive oxygen species in H2O2-treated HepG2 cells [6].
DPPH free radical scavenging activity and ferric-reducing
antioxidant power values determined for the essential oil
were26.1 ±1.2%and2.3 ±0.3mM,respectively,whichwere
signiﬁcantly higher than those of various fruit pulp extracts
[7]. Hesperidin and naringin were present in fruit juice.
Caﬀeic, p-coumaric, ferulic, and vanillic acid are also present
in the fruit juice [8]. A C-C linked bisacridone alkaloid,
buntanbismine,wasisolatedfromthestembarkofC.grandis
[9]. C. maxima essential oil is composed of α-Pinene,
Sabenine, β-Pinine, Methyl heptenone, β-myrcene, Hexanal,2 ISRN Pharmacology
Sabenine, DL-Limonene, t-Ocimene, Linalool, 1-Hexene,
4-methyl;1-Hexene,3,3-dimethyl;Geranylformate,Z-Citral,
Geranyl formate, E-Citral, Geranyl acetate, β-Farnesene, and
at 750ppm and 1000ppm it inhibited mycelia growth of
A. ﬂavus [10]. The antiproliferative eﬀect of an immature
C. grandis fruit extract was investigated using U937 human
leukaemia cells. The induction of apoptosis was conﬁrmed
by caspase-3 activity assays and by immunoblotting using
antibodies against Bcl-2, Bax, poly(ADPribose) polymerase,
caspase-9, and caspase-3 [11].
2.MaterialsandMethods
2.1. Plant Material. The leaves of C. maxima were dried
under shade and powdered by mechanical grinder. About
500g of the plant material was successively extracted with
petroleum ether and methanol in a Soxhlet apparatus. The
methanol was then evaporated under reduced pressure to get
the crude extract (MECM, yield 18.1%).
2.2. Phytochemical Screening. The plant extracts were sub-
jected to screening for various phytochemicals employing
standard protocol for determining the presence of steroids,
alkaloids, tannins, ﬂavonoids, glycosides, and so forth [12].
2.3. Chemicals. Sodium chloride, trypan blue, methyl violet,
methylene blue, 5-ﬂuorouracil (Merck ltd., Mumbai, India).
All other reagents used were of the highest analytical grade.
2.4. Acute Toxicity. The acute toxicity of the extract was
determined according to the OECD guideline no. 420. Male
albino mice weighing 27–30g were used for this study.
MECM was given to four groups (n = 5) of animals at 5, 50,
300,and2000mg/kgBWp.o.Thetreatedanimalswereunder
observation for 14 days, for mortality and general behaviour.
No death was observed till the end of the study. The test
samples were found to be safe up to the dose of 2000mg/kg.
2.5. Animals. Male Swiss albino mice weighing 20–22g were
used for present investigation. They were obtained from B.
N. Ghosh and Co., Kolkata. They were acclimatized to the
laboratory conditions prior to the study for seven days. The
a n i m a l sw e r ek e p ta t2 5± 2◦C and a relative humidity of 40–
45% with alternative day and night cycles of 12 hours each.
The animals had free access to pellet food (Hindustan Lever,
Mumbai, India) and water ad libitum.
2.6. Transplantation of Tumor. EAC cells were obtained from
Chittaranjan National Cancer Institute (CNCI), Kolkata,
India. The EAC cells were maintained in in vivo in Swiss
albino mice by peritoneal transplantation of 2 × 106 cells per
mouse every 10 days. Ascitic ﬂuid was drawn from tumor-
bearing mice at the log phase (days 7-8 of tumor bearing) of
the tumor cells. Each animal received 0.1mL of tumor cell
suspension containing 2 × 106 tumor cells i.p.
2.7. Treatment Schedule. 60 Swiss albino mice were divided
into ﬁve groups (n = 12). All groups except Group I received
EAC cells (2 × 106 cells/mouse i.p.) and this was taken as
the 0th day. Group I served as saline control (5mL/kg 0.9%
NaCl w/v p.o). Group II served as EAC control. Twenty-four
hours after EAC transplantation, Groups III and IV received
MECM (200 and 400mg/kg BW i.p.), and Group V received
reference drug 5-ﬂuorouracil (5-FU, 20mg/kg BW i.p.) daily
for nine consecutive days [13]. Twenty-four hours of last
dose and 18h of fasting, six animals of each group were
sacriﬁced by cervical dislocation for measurement of tumor
andbiochemicalparameters,andtherestwerekeptwithfood
and water ad libitum to check the percentage increase in life
span. Blood was collected by cardiac puncture for estimation
of the haematological parameters. The antitumor activity of
the MECM was measured in EAC animals with respect to the
following parameters.
2.8. Tumor Volume. The ascitic ﬂuid was collected from the
peritoneal cavity, and volume was measured by taking it in a
graduated centrifuge tube.
2.9. Percentage Increase in Life Span. The eﬀect of MECM on
percentage increases in life span was calculated on the basis
of mortality of the experimental mice [13].
ILS(%) =

mean survival time of treated group
mean survival time of control group
−1

×100,
Mean survival time
∗ =
ﬁrst death + last death
2
.
(1)
∗Time is denoted by days.
2.10. Tumor Cell Count. The ascitic ﬂuid was taken in a
WBC pipette and diluted to 100 times. Then a drop of
the diluted cell suspension was placed on the Neubauer’s
counting chamber, and the numbers of cells in the 64 small
squares were counted.
2.11. Viable/Nonviable Tumor Cell Count. The viability and
nonviability of the cell were checked by trypan blue assay.
The cells were stained with trypan blue (0.4% in normal
saline) dye. The cells that did not take up the dye were viable,
and those that took the dye were nonviable. These viable and
nonviable cells were counted.
Cell counter =
Number of cells ×dilution factor
Area ×thickness of liquid ﬁlm
. (2)
2.12. Hematological Parameters. Blood was used for the
estimation of hemoglobin (Hb) content, red blood cell
(RBC) count, and white blood cell (WBC) count by standard
procedures.
2.13. Biochemical Estimation. Blood collected by cardiac
puncture was used for the determination of SGPT, SGOT,
and ALP.
2.14. Statistical Analysis. All data are expressed as mean
± SEM (n = 6 mice per groups). Statistical signiﬁcanceISRN Pharmacology 3
Table 1: Eﬀect of MECM on survival time, increased life span, tumor volume, viable cell count, and nonviable cell count of EAC tumor
bearing mice (n = 6).
Parameters EAC control 200mg/kg MECL 400mg/kg MECL 20mg/kg 5-FU
Tumor volume (mL) 3.8 ± 0.26 2.15 ± 0.44∗ 1.56 ± 0.22∗ 0.73 ± 0.18∗
MST (days) 19.5 28 34 40.5
%ILS 0 43.59 74.36 107.69
Viable cell ×107 7.47 ± 0.14 1.71 ± 0.06∗ 1.39 ± 0.15∗ 0.93 ± 0.04∗
Nonviable cell ×107 0.32 ± 0.03 1.6 ± 0.04∗∗ 2.34 ± 0.05∗∗ 2.72 ± 0.05∗∗
Total cell ×107 7.79 3.31 3.73 3.65
Viable% 95.89 51.66 37.27 25.48
Nonviable% 4.11 48.34 62.73 74.52
∗Experimental groups are compared with control group (P<. 001).
∗∗Experimental groups are compared with control group (P<. 05).
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Figure 1: Eﬀect of MECM on haematological parameters of EAC
cell-bearing mice (n = 6). Experimental groups are compared with
EAC control group (P<. 001)
(p) was calculated by one-way ANOVA between the treated
groups and the EAC control followed by Dunnett’s test of
signiﬁcance where P<. 05 and P<. 001 were considered
to be signiﬁcant and highly signiﬁcant, respectively.
3. Results
Intraperitonial administration of MECM at the dose levels
of 200 and 400mg/kg BW increased the life span, nonviable
tumor cell count and decreased the tumor volume, viable
tumor cell count as compared to the EAC control mice as
shown in Table 1.
MECM also restored the haematological parameters
towardsnormallevelwhencomparedwithEACcontrolmice
as shown in Figure 1.
The eﬀects of MECM on diﬀerent serum biochemical
parameters are given in Figure 2.
4. Discussion
The present study showed that MECM signiﬁcantly dec-
reased the WBC count and prolonged the life span of the
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Figure 2: Eﬀe c to fM E C Mo nd i ﬀerent biochemical parameters in
EAC-treated mice (n = 6). Experimental groups are compared with
EAC control group (P<. 001).
EAC-treated groups as compared to those of the EAC
control group. One of the major criteria of judging good
anticancer drugs is that it should be able to prolong the life
and decrease the leucocyte count [14]. Reduced volume of
tumor and increased life span also indicated decrease of
cell division [13]. The anaemia associated with carcinoma
was also restored to normal levels when compared to the
control group as indicated by the increased RBC count and
hemoglobin level. These indicate that MECM has no toxic
eﬀects on the haematological system [15].
The serum biochemical parameters were restored to nor-
mal levels comparable to saline control indicating protection
from the tumor cell-induced hepatotoxicity by MECM [16].
Preliminary phytochemical study indicated that MECM
contained ﬂavonoids, alkaloids, tannins, and saponin. In a
previous study conducted by the authors the antioxidant
activity of MECM was established against diﬀerent reactive
oxygen and nitrogen species [17].
The ﬂavonoids and limonoids present in citrus plants
are postulated to be the cause of their antitumor and anti-
inﬂammatory eﬀects [18]. Flavonoids have a chemopre-
ventive role in cancer by means of their eﬀect in signal4 ISRN Pharmacology
transduction in cell proliferation and angiogenesis [13].
As mentioned earlier immature hexane fruit extract of
pomelo was investigated for its antiproliferative activity and
has already been proven to induce apoptosis against U937
human leukemia cell line [11], therefore a similar mode of
action can be proposed for MECM.
Therefore it can be concluded from this study that Citrus
maxima possesses potent anticancer activity which can be
attributed to the ﬂavonoids present in it which can therefore
serveasasteppingstoneforthediscoveryofanewanticancer
agent.
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